 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- anti-CD33 CAR T / City of Hope, National Cancer Institute, CD33CART / Center for International Blood and Marrow Transplant Research
Success of Centralized Manufacturing of CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML () - Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_858;
P1/2
Despite wide inter-patient heterogeneity of apheresis products, centralized manufacturing of CD33CART was feasible in children and young adults with r/r AML. Correlative analyses characterizing CD33CART products are ongoing.
- | CD33CART / Center for International Blood and Marrow Transplant Research
Enrollment closed, Enrollment change: Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 30, 2023
P1/2, N=52, Active, not recruiting, Sponsor: Center for International Blood and Marrow Transplant Research
Correlative analyses characterizing CD33CART products are ongoing. Recruiting --> Active, not recruiting | N=37 --> 52
- anti-CD33 CAR T / City of Hope, National Cancer Institute, CD33CART / Center for International Blood and Marrow Transplant Research
CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter Trial (SDCC - Room 6CF) - Nov 3, 2023 - Abstract #ASH2023ASH_4898;
P1/2
CD33CART expansion was best in subjects treated at DL4 (1 x 10 7 /kg) with MRD negative CRs and transient myeloid aplasia occurring in 2 of 5 (40%) subjects evaluable for response (Table). Based on early clinical efficacy at DL4, enrollment continues in the phase 2 portion.
- | CD33CART / Center for International Blood and Marrow Transplant Research
Enrollment open: Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 8, 2020
P1/2, N=34, Recruiting, Sponsor: Center for International Blood and Marrow Transplant Research
Based on early clinical efficacy at DL4, enrollment continues in the phase 2 portion. Not yet recruiting --> Recruiting
- | CD33CART / Center for International Blood and Marrow Transplant Research
New P1/2 trial: Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 2, 2019
P1/2, N=43, Not yet recruiting, Sponsor: Center for International Blood and Marrow Transplant Research